MedTrace Logo

Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors

NCT04060290 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-02-28

No results posted yet for this study

Summary

This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.

Conditions

Interventions

OTHER

Observational study

Observational study of this study, no interventions involved

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wei Zhao · Shiyao Group Ouyi Pharmaceutical Co., Ltd.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060290 on ClinicalTrials.gov